Show simple item record

dc.contributor.authorChong, Curtis Robert
dc.contributor.authorWirth, Lori Julin
dc.contributor.authorNishino, Mizuki
dc.contributor.authorChen, Aileen Betty
dc.contributor.authorSholl, Lynette Marie
dc.contributor.authorKulke, Matthew H
dc.contributor.authorMcNamee, Ciaran
dc.contributor.authorJanne, Pasi Antero
dc.contributor.authorJohnson, Bruce Evan
dc.date.accessioned2017-05-18T16:33:56Z
dc.date.issued2014
dc.identifier.citationChong, Curtis R., Lori J. Wirth, Mizuki Nishino, Aileen B. Chen, Lynette M. Sholl, Matthew H. Kulke, Ciaran J. McNamee, Pasi A. Jänne, and Bruce E. Johnson. 2014. “Chemotherapy for Locally Advanced and Metastatic Pulmonary Carcinoid Tumors.” Lung Cancer 86 (2) (November): 241–246. doi:10.1016/j.lungcan.2014.08.012.en_US
dc.identifier.issn0169-5002en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32706203
dc.description.abstractObjectives The optimal management of locally advanced and metastatic pulmonary carcinoid tumors remains to be determined. Materials and methods A retrospective review was conducted on patients with typical and atypical pulmonary carcinoid tumors treated at our institutions between 1990 and 2012. Results 300 patients were identified with pulmonary carcinoid, (80 patients with atypical carcinoid), of whom 29 presented with metastatic disease (16 atypical). Of evaluable patients, 26 (41%) with stages I–III atypical carcinoid tumors recurred at a median time of 3.7 years (range, 0.4–32), compared to 3 (1%) patients with typical carcinoid (range, 8–12.3). 39 patients were treated with chemotherapy, including 30 patients with metastatic disease (27 atypical), and 7 patients were treated with adjuvant platinum–etoposide chemoradiation (6 atypical, 1 typical, 6 stage IIIA, 1 stage IIB). At a median follow-up of 2 years there were 2 recurrences in the 7 patients receiving adjuvant treatment. Median survival after diagnosis of metastatic disease for patients with atypical pulmonary carcinoid was 3.3 years with a 5-year survival of 24%. Treatment regimens showing efficacy in pulmonary carcinoid include 15 patients treated with octreotide-based therapies (10% response rate (RR), 70% disease control rate (DCR), 15 month median progression-free survival (PFS)), 13 patients treated with etoposide + platinum (23% RR, 69% DCR, 7 month median PFS), and 14 patients treated with temozolomide-based therapies (14% RR, 57% DCR, 10 month median PFS). 8 of 10 patients with octreotide-avid disease treated with an octreotide-based regimen experienced disease control (1 partial response, 7 stable disease) for a median of 18 months (range 6–72 months). Conclusions These results support our previous finding that a subset of pulmonary carcinoid tumors are responsive to chemotherapy.en_US
dc.language.isoen_USen_US
dc.publisherElsevier BVen_US
dc.relation.isversionofdoi:10.1016/j.lungcan.2014.08.012en_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293119/en_US
dash.licenseOAP
dc.titleChemotherapy for locally advanced and metastatic pulmonary carcinoid tumorsen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalLung Canceren_US
dash.depositing.authorSholl, Lynette Marie
dc.date.available2017-05-18T16:33:56Z
dc.identifier.doi10.1016/j.lungcan.2014.08.012*
dash.authorsorderedfalse
dash.contributor.affiliatedMcNamee, Ciaran
dash.contributor.affiliatedWirth, Lori
dash.contributor.affiliatedChen, Aileen
dash.contributor.affiliatedChong, Curtis Robert
dash.contributor.affiliatedJohnson, Bruce
dash.contributor.affiliatedKulke, Matthew
dash.contributor.affiliatedJanne, Pasi
dash.contributor.affiliatedSholl, Lynette


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record